引用本文:
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3503次   下载 3106 本文二维码信息
码上扫一扫!
分享到: 微信 更多
鼻咽癌海马组织勾画后VMAT与IMRT技术的剂量学研究
刘跃华, 王佳浩, 赵鹏军, 郑如珍, 邓清华
杭州市肿瘤医院放疗科
摘要:
目的比较在鼻咽癌勾画海马组织作为危及器官后容积旋转调强放疗(VMAT)与适形调强放疗(IMRT)技术的剂量学差异,评估VMAT技术在鼻咽癌海马组织勾画后的临床应用价值。方法选取10例鼻咽癌患者作为研究对象,均制定双弧VMAT与7野IMRT两种计划。在满足临床治疗要求的条件下,新增海马组织作为危及器官进行优化计算,比较两种技术的靶区均匀指数、适形指数、危及器官剂量分布、监测单元与治疗时间等。结果两种技术均能满足临床的治疗要求。VMAT技术较IMRT技术具有更好的靶区均匀性与适形性(均P<0.05);VMAT技术较IMRT技术在海马组织的最大剂量、平均剂量上分别减少31.7%、42.7%(均P<0.05),10Gy剂量体积、5Gy剂量体积分别减少46.3%、27.2%(均P<0.05);在晶状体的最大剂量上减少38.7%(P<0.05);在监测单元与治疗时间上,VMAT技术较IMRT技术也均减少(均P<0.05)。结论在鼻咽癌患者放疗中进行海马组织勾画后,VMAT技术较IMRT技术有明显的剂量学优势,值得在临床上推广应用。
关键词:  鼻咽癌 海马 VMAT IMRT 剂量学
DOI:
分类号:
基金项目:
Dosimetric comparison of VMAT and IMRT in hippocampus delineation of patients with nasopharyngeal carcinoma
Liu Yuehua, Wang Jiahao, Zhao Pengjun, Zheng Ruzhen, Deng Qinghua
Hangzhou Cancer Hospital
Abstract:
Objective To analyze the dosimetric characteristics and clinical application of VMAT technique in hippocampus delineation of patients with nasopharyngeal carcinoma. Methods Ten patients with nasopharyngeal carcinoma were included in the study. The therapy was designed as two plans: two-arc VMAT and 7-field IMRT. According to clinical requirement, the hippocampus was added as a new OAR for recalculating, and the target homogeneity, conformity, OARs dose distribution, MU and treatment time were compared between two techniques. Results Both plans met the clinical requirement. VMAT plan had better target homogeneity and conformity than IMRT plan (all P<0.05). Compared with IMRT plan, VMAT plan reduced HPC max dose and mean dose by 31.7% and 42.7% (P <0.05), reduced HPC 10Gy dose-volume (V10) and 5Gy dose-volume (V5) by 46.3% and 27.2%(P<0.05); VMAT reduced the lens max dose by 38.7%(P<0.05), and reduced MU and treatment time (P<0.05). Conclusion VMAT is superior to IMRT in dosimetric characteristics for nasopharyngeal carcinoma with hippocampus delineation.
Key words:  Nasopharyngeal carcinoma Hippocampus VMAT IMRT Dosimetry